Two RTP-based early-stage biotech companies - Metabolon (www.metabolon.com) and Qualyst (www.qualyst.com) - have named leading medical professionals to their newly created Scientific Advisory Boards. Metabolon's advisory board includes global thought leaders and pioneers in the field of metabolomics, a new approach for the discovery and development of drugs and the early diagnosis of disease states. Founding members of Metabolon's Scientific Advisory Board include the following medical professionals:
- Hamilton O. Smith, M.D., Chairman of the Scientific Advisory Board and Scientific Director of the Institute of Biological Energy Alternatives. In 1978, Dr. Smith was a co-recipient of the Nobel Prize in Medicine for the discovery of Type II restriction enzymes, which led to the development of recombinant DNA technology.
- J. Craig Venter, Ph.D., well known for leading Celera to the successful sequencing of the human genome.
- Paul Schimmel, Ph.D., Scientific Advisory Board member and Co-Founder; also a professor at The Scripps Research Institute.
- Oliver Smithies, D. Phil., professor of pathology and laboratory medicine at UNC-Chapel Hill.
- M. Flint Beal, M.D., Chairman of the Department of Neurology and Neuroscience at the Weill Medical College of Cornell University and Director of the Neurology Service at the New York Presbyterian Cornell Campus.
- Donald W. Kufe, M.D., is Chief of Cancer Pharmacology in the Department of Adult Oncology at the Dana-Farber Cancer Institute, Director of the Harvard Phase I Oncology Program and a professor of medicine at Harvard Medical School.
Qualyst is developing technologies for the drug discovery and development marketplace. Members of Qualyst's Scientific Advisory Board include the following world-renowned scientists:
- Kim L.R. Brouwer, Pharm.D., Ph.D., Chair of the Scientific Advisory Board, co-founder of Qualyst, and Professor at UNC-Chapel Hill's School of Pharmacy.
- Ronald T. Borchardt, Ph.D., Solon E. Summerfield Distinguished Professor of Pharmaceutical Chemistry, The University of Kansas.
- Ken R. Brouwer, Ph.D., RPh., Vice President of Research and Development, Qualyst, Inc.
- Richard B. Kim, M.D. Associate Professor, Department of Medicine and Pharmacology, Vanderbilt University.
- Anthony Y.H. Lu, Ph.D., Adjunct Professor (In Residence), The Susan Lehman Cullman Laboratory for Cancer Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey.
- Gerald T. Miwa, Ph.D., Vice President, Drug Metabolism and Pharmacokinetics, Millennium Pharmaceuticals.
- Gary M. Pollack, Ph.D., Professor at The University of North Carolina at Chapel Hill-School of Pharmacy, and co-founder of Qualyst.
Metabolon is a CED member.